Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221–223).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab
BMC Cancer Open Access 12 July 2023
-
Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Oncology and Therapy Open Access 21 March 2023
-
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
British Journal of Cancer Open Access 09 November 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Montagut, C. et al. Nat. Med. 18, 221–223 (2012).
Jonker, D.J. et al. N. Engl. J. Med. 357, 2040–2048 (2007).
Vermorken, J.B. et al. N. Engl. J. Med. 359, 1116–1127 (2008).
Karapetis, C.S. et al. N. Engl. J. Med. 359, 1757–1765 (2008).
De Roock, W. et al. Lancet Oncol. 11, 753–762 (2010).
Amado, R.G. et al. J. Clin. Oncol. 26, 1626–1634 (2008).
Bardelli, A. & Siena, S. J. Clin. Oncol. 28, 1254–1261 (2010).
Wadlow, R.C. et al. Oncologist published online, 10.1634/theoncologist.2011-0452 (30 December 2011).
Jänne, P.A., Gray, N. & Settleman, J. Nat. Rev. Drug Discov. 8, 709–723 (2009).
Yonesaka, K. et al. Sci. Transl. Med. 3, 99ra86 (2011).
Bertotti, A. et al. Cancer Discov. 1, 509–523 (2011).
Benavente, S. et al. Clin. Cancer Res. 15, 1585–1592 (2009).
Li, C., Iida, M., Dunn, E.F., Ghia, A.J. & Wheeler, D.L. Oncogene 28, 3801–3813 (2009).
Lu, Y. et al. Cancer Res. 67, 8240–8247 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bardelli, A., Jänne, P. The road to resistance: EGFR mutation and cetuximab. Nat Med 18, 199–200 (2012). https://doi.org/10.1038/nm.2646
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2646
This article is cited by
-
RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab
BMC Cancer (2023)
-
Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Oncology and Therapy (2023)
-
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
British Journal of Cancer (2023)
-
NFAT5 promotes oral squamous cell carcinoma progression in a hyperosmotic environment
Laboratory Investigation (2021)
-
Neurotrophins and their involvement in digestive cancers
Cell Death & Disease (2019)
